Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageHaemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components.
In the company’s own words · 10-K filed May 20, 2026 · SEC EDGAR
Business segments
Jun 2026 · $339.4MThe company’s own SEC segment disclosure.
- Apheresis$191.3M56%
- Med Surg$148.1M44%
Haemonetics Corporation (HAE) reported revenue of $346M in Q4 2026 (quarter ended Mar 28, 2026), up 4.8% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $20M. For the full year FY2026, revenue was $1.33B (−2.0% year on year) and net income $97M. Its largest segment in Jun 2026 was Apheresis at $191M, 56% of the disclosed total, ahead of Med Surg at 44%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.